Modulation effect of bis (alpha-furancarboxylato) oxovanadium (IV) on blood glucose in diabetic rats.
- Author:
Li-Hui GAO
1
;
Ming-Jin XIE
;
Ling LI
;
Wei-Ping LIU
;
Yan-Rong LI
;
Zhi-He CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Blood Glucose; metabolism; Diabetes Mellitus, Experimental; blood; metabolism; Dose-Response Relationship, Drug; Glucose Tolerance Test; Glycated Hemoglobin A; metabolism; Hypoglycemic Agents; administration & dosage; pharmacology; Insulin; blood; Liver Glycogen; metabolism; Male; Organometallic Compounds; administration & dosage; pharmacology; Random Allocation; Rats; Rats, Sprague-Dawley; Vanadium; administration & dosage; pharmacology
- From: Acta Pharmaceutica Sinica 2005;40(6):496-500
- CountryChina
- Language:Chinese
-
Abstract:
AIMTo study the hypoglycemic effect of bis (alpha-furancarboxylato) oxovanadium (IV) (VO-FA) in normal rats and streptozotocin (STZ)-diabetic rats.
METHODSRats were injected intraperitoneally STZ 50 mg.kg(-1) to induce diabetes. Blood glucose, glycohemoglobin, glycogen and serum insulin were observed after administering intragastrically VO-FA for four weeks.
RESULTSAfter 2 weeks administration, VO-FA reduced the blood glucose in STZ-rats (P < 0. 01) dose-dependently, and up to 4 weeks the blood glucose was normalized (below 11.1 mmol.L(-1)) in some of STZ-rats, whereas did not decrease in normal rats. After administration of VO-FA at the dosage of 56.8 and 113.6 mg.kg(-1), the serum insulin levels were lowered in normal rats and STZ-rats, respectively. Moreover, VO-FA reduced glycohemoglobin, improved the glucose tolerance, and increased the liver glycogen and muscle glycogen contents in STZ-rats in a dose-dependent manner (P < 0. 05, P < 0. 01), but not in normal rats.
CONCLUSIONVO-FA could improve the glycometabolism in STZ-rats, but not in normal rats.
